Healthcare Strategies Group provides a unique blend of strategic advisory services and operational business development and general management support to the diagnostic and med-tech industries. The company’s advisory services are focused on commercial strategy development through to operational business development, market access and general management support.
The founder, Dr. Iain Miller, has extensive international experience, having split his career between the US and the EU. His client and broader experience base spans GE Healthcare, Biomerieux, J&J, Philips, Myriad Genetics and the UK Government Technology Strategy Board, in addition to various SMEs and investor groups. In addition to his 20-year US experience, Dr. Miller has worked extensively in the UK and EU marketplace, including major market access policy projects with European thought leaders. He is also a founding Board member of the European Personalized Medicine Association and has been very active in the UK stratified medicine and broader med-tech ecosystems. Within the UK Iain sits on the NICE Technology Appraisal Committee which reviews drugs and companion test products and is a member of the Oxford Bioscience Network Med-Tech Advisory Board. He also frequently serves as an assessor for the UK Technology Strategy Board (Innovate UK). Healthcare Strategies Group is based in London, where Dr. Miller and his associates frequently provide market bridging services between the US and the EU, including on-the-ground UK / EU market development for US companies and US market development support for UK-based companies.
Please click here for more information on the services provided by Healthcare Strategies Group or here for more information on our clients and illustrative projects. Detailed information on the Founder and Team can be found here . Information on Company News and Events, including upcoming publications and links to our thought leadership articles, can be found here .
****** Latest News:
December 2014: The European Personalised Medicine Association (EPEMED) releases 51 page report “Enhancing Patient Access to Drug Diagnostic Products in the EU”. Dr. Miller served on the Steering Committee of this 2 year initiative and is interviewed on the Epemed website about the report. Copy available upon request.
September 2014: Iain Miller publishes new peer-reviewed article “Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets” in Current Pharmacogenomics and Personalized Medicine journal. Copy available upon request.
August 2014: Iain Miller, Founder of Healthcare Strategies Group, accepts invitation to join the NICE (UK) Technology Appraisal Committee.